A single month, reconciled. Every figure below is traced back to dispensing data, the Drug Tariff and your remittances.
A line that made money in October can quietly turn. The dip in February is concession-driven — and recoverable.
Net cost versus what you were actually reimbursed, line by line — so loss-making and over-tariff items stop hiding inside the average. Click a column to sort; filter by flag.
| Item▾ | Net cost▾ | Reimbursed▾ | Margin £▾ | Flag▾ |
|---|---|---|---|---|
| Total — 16 lines shown | £42,180 | £61,200 | — |
Net margin by therapeutic class. Two classes carry the practice; two are quietly draining it.
Not just charts — a ranked list of what to do, with the value at stake. None of it requires changing what you prescribe.
Wholesaler rebate running ~13% against a ~25% achievable rate. The single biggest lever — a procurement conversation, not a clinical one.
Lines bought above reimbursement during shortages. ≈ £11,100 over six months versus what the Tariff paid back.
≈ £19k a year of contribution that evaporates if specific price concessions are withdrawn. Worth watching and hedging.
A cheaper same-month source existed on several lines. Ordering discipline, not concessions — quick to fix.
Every review ships these — finished, audited and ready to act on. Open the samples below (fictional data).
Send us a period of data and we'll show you exactly where your dispensary is leaking — and what it's worth to fix.